Implications for Crohn's Disease Management

Aurélie Blondeaux,Caroline Valibouze,Silvia Speca,Christel Rousseaux,Caroline Dubuquoy,Hélène Blanquart,Philippe Zerbib,Pierre Desreumaux,Benoît Foligné,Marie Titécat

DOI: https://doi.org/10.3390/ijms25042164

IF: 5.6

2024-02-11

International Journal of Molecular Sciences

Abstract:The therapeutic management of Crohn's disease (CD), a chronic relapsing–remitting inflammatory bowel disease (IBD), is highly challenging. Surgical resection is sometimes a necessary procedure even though it is often associated with postoperative recurrences (PORs). Tofacitinib, an orally active small molecule Janus kinase inhibitor, is an anti-inflammatory drug meant to limit PORs in CD. Whereas bidirectional interactions between the gut microbiota and the relevant IBD drug are crucial, little is known about the impact of tofacitinib on the gut microbiota. The HLA-B27 transgenic rat is a good preclinical model used in IBD research, including for PORs after ileocecal resection (ICR). In the present study, we used shotgun metagenomics to first delineate the baseline composition and determinants of the fecal microbiome of HLA-B27 rats and then to evaluate the distinct impact of either tofacitinib treatment, ileocecal resection or the cumulative effect of both interventions on the gut microbiota in these HLA-B27 rats. The results confirmed that the microbiome of the HLA-B27 rats was fairly different from their wild-type littermates. We demonstrated here that oral treatment with tofacitinib does not affect the gut microbial composition of HLA-B27 rats. Of note, we showed that ICR induced an intense loss of bacterial diversity together with dramatic changes in taxa relative abundances. However, the oral treatment with tofacitinib neither modified the alpha-diversity nor exacerbated significant modifications in bacterial taxa induced by ICR. Collectively, these preclinical data are rather favorable for the use of tofacitinib in combination with ICR to address Crohn's disease management when considering microbiota.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The problems that this paper attempts to solve mainly focus on the following aspects:

1. **Challenges in Crohn's disease management**: Crohn's disease (CD) is a chronic relapsing inflammatory bowel disease (IBD), and its treatment is very challenging. Surgical resection (such as ileocecal resection) is a necessary treatment method, but the postoperative recurrence rate is high, which makes it particularly important to find effective prevention and treatment methods.

2. **The effect of tofacitinib on the gut microbiota**: Tofacitinib is an oral small - molecule Janus kinase inhibitor with anti - inflammatory effects, aiming to reduce the recurrence of Crohn's disease patients after surgery. However, little is known about the specific effects of tofacitinib on the gut microbiota. Therefore, the researchers hope to explore the potential effects of tofacitinib on the gut microbiota through this study.

3. **The effect of ileocecal resection on the gut microbiota**: Ileocecal resection (ICR) is a common surgical method for treating Crohn's disease. However, the gut microbiota will change significantly after surgery, and these changes may be related to postoperative recurrence. Therefore, the researchers hope to evaluate the specific effects of ICR on the gut microbiota.

4. **The effect of the combined use of tofacitinib and ICR**: The researchers also hope to evaluate the comprehensive effects of the combined use of tofacitinib and ICR on the gut microbiota to determine whether this combined treatment method is helpful for improving the management of Crohn's disease.

Specifically, the researchers used the HLA - B27 transgenic rat model. Through metagenomics technology, they first determined the composition and characteristics of the fecal microbiota of HLA - B27 rats under baseline conditions, and then evaluated the effects of tofacitinib treatment alone, ICR surgery alone, and the combined use of the two on the gut microbiota. The research results show that tofacitinib treatment itself has little effect on the gut microbiota, while ICR surgery significantly changes the diversity and composition of the gut microbiota. These findings provide important references for the management and treatment of Crohn's disease.